You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEplerenone
Accession NumberDB00700  (APRD00707)
TypeSmall Molecule
GroupsApproved
Description

Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

Structure
Thumb
Synonyms
SynonymLanguageCode
EpoxymexrenoneNot AvailableNot Available
InspraNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Inspratablet, film coated25 mgoralG.D. Searle LLC Division of Pfizer Inc2002-09-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Inspratablet, film coated50 mgoralG.D. Searle LLC Division of Pfizer Inc2002-09-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Inspratablet25 mgoralRebel Distributors Corp2002-09-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Eplerenonetablet, film coated25 mgoralGreenstone LLC2002-09-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Eplerenonetablet, film coated50 mgoralGreenstone LLC2002-09-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Inspratablet25 mgoralPfizer Canada IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Inspratablet50 mgoralPfizer Canada IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eplerenonetablet25 mgoralEon Labs, Inc.2008-08-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Eplerenonetablet50 mgoralEon Labs, Inc.2008-08-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Eplerenonetablet50 mgoralRebel Distributors Corp.2008-08-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Eplerenonetablet25 mgoralPhysicians Total Care, Inc.2009-09-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Eplerenonetablet25 mgoralApotex Corp2008-07-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Eplerenonetablet50 mgoralApotex Corp2008-07-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number107724-20-9
WeightAverage: 414.4914
Monoisotopic: 414.204238692
Chemical FormulaC24H30O6
InChI KeyJUKPWJGBANNWMW-VWBFHTRKSA-N
InChI
InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1
IUPAC Name
methyl (1'R,2R,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0¹,¹⁷.0²,⁷.0¹¹,¹⁵]octadecan]-6'-ene-9'-carboxylate
SMILES
[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as spironolactones and derivatives. These are steroid lactones with a structure based on the spironolactone skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentSpironolactones and derivatives
Alternative Parents
Substituents
  • Spironolactone
  • Oxepane
  • Gamma butyrolactone
  • Dicarboxylic acid or derivatives
  • Methyl ester
  • Oxolane
  • Cyclic ketone
  • Lactone
  • Ketone
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Oxirane
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
PharmacodynamicsEplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.
Mechanism of actionEplerenone binds to the mineralocorticoid receptor and thereby blocks the binding of aldosterone (component of the renin-angiotensin-aldosterone-system, or RAAS). Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, blood vessels, and brain) tissues and increases blood pressure through induction of sodium reabsorption and possibly other mechanisms.
AbsorptionThe absolute bioavailability of eplerenone is unknown.
Volume of distribution
  • 43 to 90 L
Protein binding50%
Metabolism

Eplerenone is metabolized primarily by CYP3A4, however, no active metabolites have been identified in human plasma.

Route of eliminationNot Available
Half life4-6 hours
Clearance
  • Apparent plasma cl=10 L/hr
ToxicityThe most likely symptoms of human overdosage would be anticipated to be hypotension or hyperkalemia. However, no cases of human overdosage with eplerenone have been reported.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Eplerenone Action PathwayDrug actionSMP00135
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9839
Blood Brain Barrier+0.8556
Caco-2 permeable+0.5076
P-glycoprotein substrateSubstrate0.7017
P-glycoprotein inhibitor IInhibitor0.8166
P-glycoprotein inhibitor IIInhibitor0.8066
Renal organic cation transporterNon-inhibitor0.7209
CYP450 2C9 substrateNon-substrate0.8229
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.6978
CYP450 2C9 substrateNon-inhibitor0.7982
CYP450 2D6 substrateNon-inhibitor0.931
CYP450 2C19 substrateNon-inhibitor0.839
CYP450 3A4 substrateNon-inhibitor0.8368
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8902
Ames testNon AMES toxic0.7496
CarcinogenicityNon-carcinogens0.9441
BiodegradationNot ready biodegradable0.9891
Rat acute toxicity2.4761 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9453
hERG inhibition (predictor II)Non-inhibitor0.7742
Pharmacoeconomics
Manufacturers
  • Apotex inc
  • Sandoz inc
  • Gd searle llc
Packagers
Dosage forms
FormRouteStrength
Tabletoral25 mg
Tabletoral50 mg
Tablet, film coatedoral25 mg
Tablet, film coatedoral50 mg
Prices
Unit descriptionCostUnit
Inspra 25 mg tablet4.87USD tablet
Inspra 50 mg tablet4.87USD tablet
Eplerenone 25 mg tablet4.18USD tablet
Eplerenone 50 mg tablet4.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States64105241999-11-052019-11-05
United States68639022000-10-102020-10-10
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySlightly solubleNot Available
logP1.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00903 mg/mLALOGPS
logP1.67ALOGPS
logP2.33ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)15.11ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area82.2 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity106.68 m3·mol-1ChemAxon
Polarizability43.79 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Bhaskar Reddy Guntoori, Svetoslav S. Bratovanov, Mohamed Ibrahim Zaki, Elena Bejan, Stephen E. Horne, “Process for the preparation and purification of eplerenone.” U.S. Patent US20080234478, issued September 25, 2008.

US20080234478
General ReferenceNot Available
External Links
ATC CodesC03DA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (136 KB)
MSDSDownload (68.2 KB)
Interactions
Drug Interactions
Drug
AbirateroneCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
AlfuzosinMay enhance the hypotensive effect of Antihypertensives.
AmifostineAntihypertensives may enhance the hypotensive effect of Amifostine.
AmilorideMay enhance the hyperkalemic effect of Potassium-Sparing Diuretics.
Ammonium chloridePotassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.
AprepitantCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
AtazanavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
Azilsartan medoxomilMay enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.
BenazeprilMay enhance the hyperkalemic effect of ACE Inhibitors.
BicalutamideCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
BiotinCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
BoceprevirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
BosentanMay decrease the serum concentration of CYP3A4 Substrates.
ButabarbitalMay enhance the hypotensive effect of Hypotensive Agents.
ButethalMay enhance the hypotensive effect of Hypotensive Agents.
CanagliflozinMay enhance the hyperkalemic effect of Eplerenone. Canagliflozin may enhance the hypotensive effect of Eplerenone.
CandesartanMay enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.
CaptoprilMay enhance the hyperkalemic effect of ACE Inhibitors.
CelecoxibNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
CilazaprilMay enhance the hyperkalemic effect of ACE Inhibitors.
CimetidineCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
ClarithromycinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
ClotrimazoleCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
ConivaptanMay increase the serum concentration of CYP3A4 Substrates.
CrizotinibCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
DabrafenibMay decrease the serum concentration of CYP3A4 Substrates.
DalteparinHeparin (Low Molecular Weight) may enhance the hyperkalemic effect of Eplerenone.
DarunavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
DasatinibMay increase the serum concentration of CYP3A4 Substrates.
DeferasiroxMay decrease the serum concentration of CYP3A4 Substrates.
DelavirdineCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
DesipramineCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
DiazoxideMay enhance the hypotensive effect of Antihypertensives.
DiflunisalNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
DiltiazemCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
DronedaroneCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
DrospirenoneMay enhance the hyperkalemic effect of Potassium-Sparing Diuretics.
DuloxetineHypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.
EnalaprilMay enhance the hyperkalemic effect of ACE Inhibitors.
EnoxaparinHeparin (Low Molecular Weight) may enhance the hyperkalemic effect of Eplerenone.
EprosartanMay enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.
EtodolacNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
FenoprofenNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
FloctafenineNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
FluconazoleFluconazole may increase the serum concentration of Eplerenone.
FosamprenavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
FosaprepitantCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
FosinoprilMay enhance the hyperkalemic effect of ACE Inhibitors.
HeparinMay enhance the hyperkalemic effect of Eplerenone.
HeptabarbitalMay enhance the hypotensive effect of Hypotensive Agents.
HexobarbitalMay enhance the hypotensive effect of Hypotensive Agents.
IbuprofenNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
IndinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
IndomethacinNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
IrbesartanMay enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.
IsavuconazoniumCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
ItraconazoleMay increase the serum concentration of Eplerenone.
IvacaftorMay increase the serum concentration of CYP3A4 Substrates.
KetoprofenNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
KetorolacNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
LisinoprilMay enhance the hyperkalemic effect of ACE Inhibitors.
LithiumEplerenone may increase the serum concentration of Lithium.
LomitapideCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
LopinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
LosartanMay enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.
LULICONAZOLEMay increase the serum concentration of CYP3A4 Substrates.
Mefenamic acidNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
MeloxicamNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
MethohexitalMay enhance the hypotensive effect of Hypotensive Agents.
MethylphenidateMay diminish the antihypertensive effect of Antihypertensives.
MifepristoneMay increase the serum concentration of CYP3A4 Substrates.
MitotaneMay decrease the serum concentration of CYP3A4 Substrates.
MoexiprilMay enhance the hyperkalemic effect of ACE Inhibitors.
NabumetoneNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
NadroparinHeparin (Low Molecular Weight) may enhance the hyperkalemic effect of Eplerenone.
NaproxenNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
NefazodoneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
NelfinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
NilotinibCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
NitrofurantoinNitrofurantoin may enhance the hyperkalemic effect of Eplerenone.
NorfloxacinCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
ObinutuzumabAntihypertensives may enhance the hypotensive effect of Obinutuzumab.
OlmesartanMay enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.
OxaprozinNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
PentobarbitalMay enhance the hypotensive effect of Hypotensive Agents.
PentoxifyllineMay enhance the hypotensive effect of Antihypertensives.
PerindoprilMay enhance the hyperkalemic effect of ACE Inhibitors.
PiroxicamNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
PosaconazoleMay increase the serum concentration of Eplerenone.
Potassium ChlorideMay enhance the hyperkalemic effect of Potassium Salts.
Potassium IodideMay enhance the hyperkalemic effect of Potassium Salts.
PrimidoneMay enhance the hypotensive effect of Hypotensive Agents.
QuinaprilMay enhance the hyperkalemic effect of ACE Inhibitors.
QuinidinePotassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.
RamiprilMay enhance the hyperkalemic effect of ACE Inhibitors.
RisperidoneHypotensive Agents may enhance the hypotensive effect of RisperiDONE.
RitonavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
RituximabAntihypertensives may enhance the hypotensive effect of RiTUXimab.
SaquinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
SecobarbitalMay enhance the hypotensive effect of Hypotensive Agents.
SiltuximabMay decrease the serum concentration of CYP3A4 Substrates.
SimeprevirMay increase the serum concentration of CYP3A4 Substrates.
SpironolactoneMay enhance the hyperkalemic effect of Potassium-Sparing Diuretics.
SulfamethoxazoleTrimethoprim may enhance the hyperkalemic effect of Eplerenone.
SulfisoxazoleCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
SulindacNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
TadalafilMay enhance the antihypertensive effect of Antihypertensives.
TelaprevirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
TelithromycinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.
TelmisartanMay enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.
TetracyclineCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.
Tiaprofenic acidNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
TinzaparinHeparin (Low Molecular Weight) may enhance the hyperkalemic effect of Eplerenone.
TocilizumabMay decrease the serum concentration of CYP3A4 Substrates.
TolmetinNonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.
TolvaptanMay enhance the hyperkalemic effect of Potassium-Sparing Diuretics.
TrandolaprilMay enhance the hyperkalemic effect of ACE Inhibitors.
TriamtereneMay enhance the hyperkalemic effect of Potassium-Sparing Diuretics.
TrimethoprimTrimethoprim may enhance the hyperkalemic effect of Eplerenone.
ValsartanMay enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.
VardenafilMay enhance the antihypertensive effect of Antihypertensives.
VoriconazoleVoriconazole may increase the serum concentration of Eplerenone.
YohimbineMay diminish the antihypertensive effect of Antihypertensives.
Food InteractionsNot Available

Targets

1. Mineralocorticoid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Mineralocorticoid receptor P08235 Details

References:

  1. Moore TD, Nawarskas JJ, Anderson JR: Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 2003 Sep-Oct;5(5):354-63. Pubmed
  2. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003 Nov 5;42(9):1666-73. Pubmed
  3. Rogerson FM, Yao Y, Smith BJ, Fuller PJ: Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Clin Exp Pharmacol Physiol. 2004 Oct;31(10):704-9. Pubmed
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

3. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

4. Cytochrome P450 11B2, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 11B2, mitochondrial P19099 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11